Pharmacology of Immunostimulants

1. Introduction/Overview

The pharmacological modulation of the immune system represents a cornerstone of modern therapeutics, extending beyond traditional antimicrobial and anti-inflammatory strategies. Immunostimulants, a diverse class of agents, are designed to enhance or potentiate specific or non-specific immune responses. Their development and clinical integration have been propelled by advances in immunology, molecular biology, and biotechnology, leading to transformative treatments for conditions previously considered intractable. The clinical relevance of these agents spans oncology, infectious diseases, immunodeficiency disorders, and as critical components of vaccine formulations. Understanding their pharmacology is essential for rational therapeutic application, given the fine balance between beneficial immune activation and the risk of excessive inflammation or autoimmunity.

Learning Objectives

• Classify major immunostimulant drugs based on their origin, target, and primary mechanism of action.
• Explain the molecular and cellular pharmacodynamics of key immunostimulant classes, including cytokine therapies, checkpoint inhibitors, and vaccine adjuvants.
• Analyze the pharmacokinetic profiles of representative immunostimulants and relate these properties to dosing regimens and therapeutic monitoring.
• Evaluate the approved clinical indications, major adverse effects, and significant drug interactions associated with immunostimulant therapies.
• Apply knowledge of special population considerations, including use in pregnancy, pediatrics, and organ impairment, to clinical decision-making.

2. Classification

Immunostimulants can be categorized through multiple lenses, including chemical nature, biological origin, cellular target, and primary immunological effect. A functional and mechanistic classification is most clinically instructive.

2.1. Cytokines and Related Agents

This category comprises naturally occurring immune signaling proteins and their engineered analogues.

• Interferons (IFNs): Type I (IFN-α, IFN-β), Type II (IFN-γ).
• Interleukins (ILs): IL-2, IL-7, IL-12, IL-15, among others.
• Colony-Stimulating Factors (CSFs): Granulocyte colony-stimulating factor (G-CSF, filgrastim), granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim).
• Other Cytokines: Tumor necrosis factor (TNF) agonists, though often used with caution due to pro-inflammatory toxicity.

2.2. Immune Checkpoint Inhibitors

These are monoclonal antibodies that block inhibitory receptors on T-cells or their ligands on tumor or antigen-presenting cells, thereby releasing pre-existing immune responses.

• Anti-CTLA-4: Ipilimumab.
• Anti-PD-1: Nivolumab, pembrolizumab.
• Anti-PD-L1: Atezolizumab, durvalumab, avelumab.

2.3. Vaccine Adjuvants

Substances incorporated into vaccine formulations to enhance, direct, and prolong the antigen-specific immune response.

• Aluminum Salts (Alum): Aluminum hydroxide, aluminum phosphate.
• Oil-in-Water Emulsions: MF59, AS03.
• Pathogen-Associated Molecular Pattern (PAMP) Mimetics: Monophosphoryl lipid A (MPL), CpG oligodeoxynucleotides.
• Particulate Systems: Virosomes, liposomes.

2.4. Non-Specific Immunomodulators

Agents with broad, often pleiotropic, effects on immune cell function.

• Bacillus Calmette-Guérin (BCG): A live, attenuated strain of Mycobacterium bovis.
• Imiquimod and Resiquimod: Toll-like receptor (TLR) 7/8 agonists.
• Thalidomide and Lenalidomide: Immunomodulatory imide drugs (IMiDs) with complex mechanisms.
• Levamisole: Historically used as an adjuvant in colorectal cancer.

2.5. Cellular Therapies and Oncolytic Viruses

This advanced category includes engineered biological entities.

• Adoptive Cell Transfer (ACT): Chimeric antigen receptor (CAR) T-cells, tumor-infiltrating lymphocytes (TILs).
• Oncolytic Viruses: Talimogene laherparepvec (T-VEC), a genetically modified herpes simplex virus.

3. Mechanism of Action

The pharmacodynamic actions of immunostimulants are intricate, engaging multiple layers of the innate and adaptive immune systems. Mechanisms are highly agent-specific.

3.1. Cytokine Pharmacology

Cytokines exert effects by binding to specific, high-affinity cell surface receptors, triggering intracellular signaling cascades, primarily the JAK-STAT pathway, which leads to altered gene expression.

• Interferons: Type I IFNs (α, β) bind to the IFNAR1/2 receptor complex, inducing an antiviral state by upregulating proteins like protein kinase R (PKR) and 2′,5′-oligoadenylate synthetase. They also enhance major histocompatibility complex (MHC) class I expression and natural killer (NK) cell activity. IFN-γ, a Type II IFN, binds to IFNGR1/2, potently activating macrophages, upregulating MHC class I and II, and promoting T-helper 1 (Th1) differentiation.
• Interleukin-2 (IL-2): Binds to a trimeric receptor (IL-2Rα/β/γ). Its primary pharmacodynamic effect is the expansion and activation of T-lymphocytes and NK cells. At high doses, it can activate regulatory T-cells (Tregs) and induce vascular leak syndrome.
• Colony-Stimulating Factors: G-CSF binds to the G-CSF receptor on neutrophil progenitors, promoting proliferation, differentiation, and mobilization from bone marrow. It also enhances neutrophil phagocytic and cytotoxic functions.

3.2. Immune Checkpoint Inhibitors

These agents function by disrupting co-inhibitory signaling pathways that tumors exploit to evade immune surveillance.

• CTLA-4 Inhibition (Ipilimumab): CTLA-4 is expressed on activated T-cells and competes with CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells (APCs). This interaction delivers an inhibitory signal. Blocking CTLA-4 enhances early T-cell activation in lymphoid tissues, increasing the T-cell repertoire against tumor antigens.
• PD-1/PD-L1 Inhibition: The PD-1 receptor on activated T-cells engages with PD-L1 (or PD-L2) expressed on tumor cells and stromal cells within the tumor microenvironment. This interaction induces T-cell exhaustion, apoptosis, and functional impairment. Anti-PD-1/PD-L1 antibodies block this interaction, restoring anti-tumor T-cell effector functions within peripheral tissues and tumors.

3.3. Vaccine Adjuvants

Adjuvants work through multiple proposed mechanisms, often summarized as the “depot effect,” “delivery system,” and “immunostimulatory” models.

• Aluminum Salts: Form a precipitate with antigen at the injection site, creating a depot for prolonged release. They also induce local inflammation, recruit antigen-presenting cells, and activate the NLRP3 inflammasome, leading to IL-1β and IL-18 release.
• TLR Agonists (e.g., MPL, CpG): MPL (a detoxified LPS derivative) is a TLR4 agonist, while CpG motifs are TLR9 agonists. Engagement of these pattern recognition receptors on APCs like dendritic cells leads to upregulation of co-stimulatory molecules (CD80, CD86) and secretion of polarizing cytokines (e.g., IL-12 for Th1 responses), enhancing antigen presentation and T-cell priming.

3.4. Non-Specific Immunomodulators

• BCG: Following intravesical instillation for bladder cancer, it attaches to fibronectin in the bladder wall. A robust local Th1-type inflammatory response is initiated, with infiltration of lymphocytes, macrophages, and granulocytes. This non-specific inflammation appears to have anti-tumor activity against residual malignant cells.
• Imiquimod: As a TLR7 agonist, it is taken up by plasmacytoid dendritic cells and other immune cells, triggering the production of type I IFNs and other pro-inflammatory cytokines. This creates a localized immune response useful for treating viral warts and certain skin cancers.
• Lenalidomide: Binds to cereblon, a component of an E3 ubiquitin ligase complex. This alters its substrate specificity, leading to the ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). In multiple myeloma, this results in direct anti-proliferative effects on malignant plasma cells and indirect immunostimulatory effects, such as enhancing T-cell and NK cell activity and reducing suppressive cytokines like TNF-α and IL-6.

4. Pharmacokinetics

The pharmacokinetic (PK) profiles of immunostimulants are highly heterogeneous, ranging from small molecules to complex proteins and cellular therapies.

4.1. Protein-Based Therapies (Cytokines, Monoclonal Antibodies)

These are generally administered parenterally (subcutaneously, intramuscularly, or intravenously) due to poor oral bioavailability from proteolytic degradation and first-pass metabolism.

• Absorption: Following subcutaneous administration, absorption into the systemic circulation occurs via lymphatic drainage, which can be slow and variable. Bioavailability typically ranges from 50% to 80% for cytokines like IFN-α and G-CSF. Monoclonal antibodies (mAbs) like checkpoint inhibitors also exhibit similar subcutaneous absorption kinetics, though many are given intravenously for more predictable exposure.
• Distribution: Volume of distribution is often limited, approximating the plasma volume (≈ 3 L) or extracellular fluid volume (≈ 8-12 L), as these large molecules do not readily cross cell membranes or the intact blood-brain barrier. Distribution may be increased in conditions like capillary leak syndrome induced by high-dose IL-2.
• Metabolism and Elimination: Primary clearance mechanisms involve proteolytic catabolism throughout the reticuloendothelial system, endothelial cells, and via target-mediated drug disposition (TMDD). Binding to its target receptor often triggers internalization and lysosomal degradation, which can be a saturable pathway leading to non-linear PK at lower doses. Renal filtration of intact proteins is minimal due to size, but renal impairment may affect the clearance of smaller cytokine fragments. Terminal half-lives vary: IFN-α (4-8 hours), G-CSF (3.5 hours), IL-2 (short, minutes to hours for the native form). Monoclonal antibodies have significantly longer half-lives (e.g., nivolumab ≈ 26 days, ipilimumab ≈ 15 days) due to FcRn-mediated recycling, which protects them from lysosomal degradation.

4.2. Small Molecule Agents

Examples include imiquimod, lenalidomide, and thalidomide.

• Absorption: Oral bioavailability is generally good but can be variable. Imiquimod is formulated for topical application, with minimal systemic absorption (≈ 1%).
• Distribution: These agents distribute more widely. Lenalidomide has a volume of distribution of approximately 50-60 L, suggesting distribution into tissues. Thalidomide readily crosses the placenta, a critical property underlying its teratogenicity.
• Metabolism and Elimination: Lenalidomide undergoes limited metabolism and is primarily excreted renally as unchanged drug (≈ 70%), with a half-life of about 3 hours. Thalidomide undergoes non-enzymatic hydrolysis in plasma, and its metabolites are renally excreted. Its half-life is approximately 5-7 hours but increases with renal impairment. Imiquimod is metabolized hepatically.

4.3. Cellular Therapies and Complex Biologicals

Pharmacokinetics for these agents is described differently, often focusing on cellular persistence, expansion, and trafficking.

• CAR T-cells: Following lymphodepleting chemotherapy and infusion, CAR T-cells undergo in vivo expansion, typically peaking within 1-2 weeks. Persistence can last months to years, monitored via qPCR for transgene DNA in peripheral blood. Distribution involves migration to tumor sites and lymphoid organs.
• Oncolytic Viruses (T-VEC): Administered by intralesional injection. Viral replication occurs within injected and non-injected tumor cells. Shedding into blood and other body fluids occurs at low levels. Clearance involves the immune system neutralizing the virus.

5. Therapeutic Uses/Clinical Applications

The clinical deployment of immunostimulants is guided by their specific mechanism and the pathophysiology of the target disease.

5.1. Oncology

This is the most prominent therapeutic area for modern immunostimulants.

• Immune Checkpoint Inhibitors: First-line or subsequent therapy for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and others with specific biomarkers (e.g., microsatellite instability-high tumors).
• Interferon-α: Historically used in adjuvant therapy for high-risk melanoma and in the treatment of hairy cell leukemia, chronic myelogenous leukemia (prior to TKIs), and AIDS-related Kaposi’s sarcoma.
• Interleukin-2 (High-Dose): A historic standard for metastatic renal cell carcinoma and melanoma, offering durable complete responses in a small subset of patients, though with significant toxicity.
• BCG: Standard intravesical therapy for non-muscle invasive bladder carcinoma (Ta, T1, and carcinoma in situ) to reduce recurrence and progression.
• CAR T-cell Therapies: Approved for specific relapsed/refractory B-cell malignancies: axicabtagene ciloleucel and tisagenlecleucel for large B-cell lymphoma and B-cell acute lymphoblastic leukemia.
• Imiquimod: Topical treatment for superficial basal cell carcinoma and actinic keratosis.

5.2. Infectious Diseases and Vaccination

• Interferons: Pegylated IFN-α, in combination with ribavirin, was the standard of care for chronic hepatitis C virus infection. IFN-β is a mainstay for relapsing-remitting multiple sclerosis, though its mechanism here may be more immunomodulatory than strictly stimulatory.
• Colony-Stimulating Factors: Primary prophylaxis of febrile neutropenia in patients receiving myelosuppressive chemotherapy with a high risk (>20%) of this complication. Also used for mobilization of hematopoietic progenitor cells for collection prior to stem cell transplantation.
• Vaccine Adjuvants: Integral components of many vaccines (e.g., hepatitis B, human papillomavirus, influenza, SARS-CoV-2) to enhance immunogenicity, allow for dose-sparing, and improve responses in immunosenescent populations.

5.3. Other Applications

• Immunodeficiency: IFN-γ is approved to reduce the frequency and severity of serious infections in chronic granulomatous disease.
• Lenalidomide/Thalidomide: Standard care for multiple myeloma and myelodysplastic syndromes with del(5q). Thalidomide is used in the treatment of erythema nodosum leprosum.

6. Adverse Effects

Adverse effects are common and often mechanism-based, stemming from excessive or misdirected immune activation.

6.1. Cytokine-Related Syndromes

These are flu-like symptoms common with interferon and interleukin therapy.

• Constitutional Symptoms: Fever, chills, rigors, fatigue, myalgia, arthralgia, and headache. These are often dose-limiting initially but may attenuate with continued therapy.
• Neuropsychiatric Effects: Depression, irritability, insomnia, and rarely, suicidal ideation, particularly associated with IFN-α therapy.
• Hematologic Toxicity: Neutropenia and thrombocytopenia can occur with interferons.
• Vascular Leak Syndrome: A serious, capillary permeability-driven complication of high-dose IL-2, leading to hypotension, edema, and multi-organ dysfunction.

6.2. Immune-Related Adverse Events (irAEs) with Checkpoint Inhibitors

These are autoimmune-like toxicities affecting any organ system, typically managed with corticosteroids and other immunosuppressants.

• Dermatologic: Maculopapular rash, pruritus, vitiligo (especially in melanoma).
• Gastrointestinal: Colitis (diarrhea, abdominal pain), hepatitis (elevated transaminases).
• Endocrine: Hypophysitis, thyroiditis (hypo- or hyperthyroidism), adrenal insufficiency, type 1 diabetes mellitus.
• Pulmonary: Pneumonitis, which can be life-threatening.
• Other: Myocarditis, nephritis, neuropathies, arthritis. Combination CTLA-4/PD-1 blockade carries a higher incidence and severity of irAEs.

6.3. Adverse Effects of Other Agents

• BCG: Local symptoms (dysuria, frequency, hematuria), systemic BCG infection (fever, pneumonitis, hepatitis) is rare but serious.
• G-CSF: Bone pain (dose-dependent), splenomegaly, rare risk of splenic rupture. Potential risk of precipitating myeloid malignancies in patients with congenital neutropenia.
• Imiquimod: Local skin reactions (erythema, erosion, flaking).
• Lenalidomide/Thalidomide: Teratogenicity (absolute contraindication in pregnancy), venous thromboembolism (requiring prophylactic anticoagulation in many settings), peripheral neuropathy (thalidomide > lenalidomide), myelosuppression.
• CAR T-cell Therapy: Cytokine release syndrome (CRS: fever, hypotension, hypoxia, multi-organ dysfunction) and immune effector cell-associated neurotoxicity syndrome (ICANS: confusion, aphasia, seizures, cerebral edema).

7. Drug Interactions

Interactions can be pharmacokinetic or pharmacodynamic, the latter being particularly significant due to the potent biological effects of immunostimulants.

7.1. Pharmacodynamic Interactions

• Enhanced Immunosuppression: Concomitant use of systemic corticosteroids or other immunosuppressive agents (e.g., TNF inhibitors, antimetabolites) may antagonize the therapeutic effect of immunostimulants, particularly checkpoint inhibitors and cytokines. However, corticosteroids are the primary treatment for managing severe irAEs, creating a complex risk-benefit scenario.
• Enhanced Myelosuppression: Combining myelosuppressive chemotherapeutics with agents like interferon may exacerbate neutropenia and thrombocytopenia.
• Increased Risk of Infection: Live vaccines (e.g., MMR, varicella, yellow fever) are generally contraindicated in patients receiving potent immunostimulants due to the risk of vaccine-associated disease. Inactivated vaccines are safe but may have suboptimal efficacy.
• Exacerbation of Autoimmunity: Use of immunostimulants in patients with pre-existing active autoimmune disease may lead to severe flares.

7.2. Pharmacokinetic Interactions

• Cytokine Effects on Drug Metabolism: Interferons, particularly IFN-α, can downregulate cytochrome P450 enzyme activity (e.g., CYP1A2, CYP2C9, CYP2D6), potentially increasing plasma concentrations of drugs metabolized by these pathways (e.g., theophylline, warfarin).
• Effects on Lenalidomide: Digoxin levels may be increased when co-administered with lenalidomide, necessitating monitoring.

7.3. Contraindications

• Absolute: Pregnancy for thalidomide, lenalidomide, and other teratogenic agents. Hypersensitivity to the drug or its components. Active, uncontrolled autoimmune disease for checkpoint inhibitors.
• Relative: Pre-existing severe cardiac, pulmonary, or renal impairment for high-dose IL-2. Organ transplantation on immunosuppression for checkpoint inhibitors (high risk of graft rejection). Concurrent active infection.

8. Special Considerations

8.1. Pregnancy and Lactation

Most immunostimulants carry significant risks during pregnancy and breastfeeding.

• Pregnancy: Many agents are contraindicated (FDA Category D or X). Thalidomide and lenalidomide are potent human teratogens, causing severe birth defects. Checkpoint inhibitors may pose a risk of fetal harm due to potential irAEs and immune activation. Cytokines like IFN-β are generally avoided. A thorough risk-benefit assessment and effective contraception are mandatory.
• Lactation: It is generally recommended to avoid breastfeeding during therapy with systemic immunostimulants, as many are excreted in milk or their effects on the infant’s developing immune system are unknown.

8.2. Pediatric and Geriatric Use

• Pediatrics: Dosing is often based on body surface area or weight. Specific agents are approved for pediatric use (e.g., G-CSF, some checkpoint inhibitors for specific cancers, CAR T-cells for ALL). Vaccination schedules must be carefully managed. The long-term effects of modulating the developing immune system require ongoing study.
• Geriatrics: No universal dose adjustment is required based on age alone. However, increased prevalence of comorbid conditions, reduced renal/hepatic function, and immunosenescence must be considered. Older patients may experience similar efficacy with checkpoint inhibitors but potentially different toxicity profiles.

8.3. Renal and Hepatic Impairment

• Renal Impairment: Critical for agents primarily renally excreted unchanged (e.g., lenalidomide). Dose reductions are required based on creatinine clearance. For monoclonal antibodies and most cytokines, renal impairment does not significantly alter PK, but the clinical condition of the patient must be assessed.
• Hepatic Impairment: The effect is less predictable. For small molecules metabolized hepatically (e.g., thalidomide), caution is advised. For protein therapeutics, hepatic impairment may alter clearance via changes in FcRn expression or endothelial function, but specific guidelines are often lacking. Baseline and periodic monitoring of liver function is essential, especially for agents causing hepatotoxicity (e.g., checkpoint inhibitors).

9. Summary/Key Points

• Immunostimulants constitute a pharmacologically diverse class of agents that enhance specific or non-specific immune function through distinct mechanisms, including cytokine signaling, checkpoint inhibition, adjuvant activity, and direct cellular activation.
• Their clinical applications are dominated by oncology, but they are also vital in managing certain infections, immunodeficiencies, and as components of effective vaccines.
• The pharmacokinetics of these agents vary dramatically; protein-based therapies have limited distribution and are catabolized, while small molecules may be orally bioavailable and renally excreted.
• Adverse effects are frequently mechanism-based. Checkpoint inhibitors are associated with a unique spectrum of immune-related adverse events across organ systems, while cytokines commonly induce flu-like syndromes. CAR T-cell therapy carries risks of cytokine release syndrome and neurotoxicity.
• Significant drug interactions are often pharmacodynamic, involving antagonism with immunosuppressants or exacerbation of toxicity. Live vaccines are generally contraindicated.
• Special population considerations are paramount: teratogenicity is a critical concern for several agents, dosing requires adjustment in renal impairment for certain drugs, and use requires caution in patients with active autoimmune disease or concurrent serious infection.

Clinical Pearls

• The therapeutic index of many immunostimulants, particularly high-dose cytokines, is narrow. Efficacy and toxicity are often two sides of the same immunological coin.
• Management of immune-related adverse events from checkpoint inhibitors hinges on early recognition, grading of severity, and prompt initiation of immunosuppressive therapy (typically corticosteroids), without unnecessarily discontinuing the anticancer agent for low-grade events.
• Prophylactic strategies, such as pre-medication with antipyretics/analgesics for cytokine therapies and thromboprophylaxis for IMiDs, are integral to tolerability and safety.
• Biomarkers, such as PD-L1 expression, tumor mutational burden, and microsatellite instability status, are increasingly used to guide the selection of checkpoint inhibitor therapy, moving towards a more personalized approach.
• Multidisciplinary collaboration among oncologists, clinical immunologists, pharmacists, and specialist nurses is essential for the safe and effective use of complex immunostimulant therapies.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.